Natco Pharma Ltd
Fundamental Score
Natco Pharma Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of NATCOPHARM across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (28.00%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (32.78%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (38.03%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 10.50 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Consistent Growth Track Record (18.26% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Excellent EPS Growth (33.70% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.
Strong Profit Growth Track Record (33.27% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (61.04x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹2778.40 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
1 factors identified
Profit Decline Concern (-23.46%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Financial Statements
Comprehensive financial data for Natco Pharma Ltd
About NATCOPHARM
Business Overview
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Company Details
Key Leadership
Corporate Events
Latest News
NATCOPHARM Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Natco Pharma Ltd (NATCOPHARM)?
As of 21 Jan 2026, 08:48 am IST, Natco Pharma Ltd (NATCOPHARM) is currently trading at ₹836.60. The stock has a market capitalization of ₹16.16K (Cr).
Is NATCOPHARM share price Overvalued or Undervalued?
NATCOPHARM is currently trading at a P/E ratio of 10.50x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Natco Pharma Ltd share price?
Key factors influencing NATCOPHARM's price include its quarterly earnings growth (Sales Growth: -0.59%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Natco Pharma Ltd a good stock for long-term investment?
Natco Pharma Ltd shows a 5-year Profit Growth of 33.27% and an ROE of 28.00%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.03 before investing.
How does Natco Pharma Ltd compare with its industry peers?
Natco Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare NATCOPHARM's P/E of 10.50x and ROE of 28.00% against the industry averages to determine its competitive standing.
What is the P/E ratio of NATCOPHARM and what does it mean?
NATCOPHARM has a P/E ratio of 10.50x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹11 for every ₹1 of annual earnings.
How is NATCOPHARM performing according to Bull Run's analysis?
NATCOPHARM has a Bull Run fundamental score of 60.3/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does NATCOPHARM belong to?
NATCOPHARM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Natco Pharma Ltd.
What is Return on Equity (ROE) and why is it important for NATCOPHARM?
NATCOPHARM has an ROE of 28.00%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Natco Pharma Ltd generates profits from shareholders' equity.
How is NATCOPHARM's debt-to-equity ratio and what does it indicate?
NATCOPHARM has a debt-to-equity ratio of 0.03, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is NATCOPHARM's dividend yield and is it a good dividend stock?
NATCOPHARM offers a dividend yield of 0.66%, which means you receive ₹0.66 annual dividend for every ₹100 invested.
How has NATCOPHARM grown over the past 5 years?
NATCOPHARM has achieved 5-year growth rates of: Sales Growth 18.26%, Profit Growth 33.27%, and EPS Growth 33.70%.
What is the promoter holding in NATCOPHARM and why does it matter?
Promoters hold 49.48% of NATCOPHARM shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is NATCOPHARM's market capitalization category?
NATCOPHARM has a market capitalization of ₹16158 crores, placing it in the Mid-cap category.
How volatile is NATCOPHARM stock?
NATCOPHARM has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for NATCOPHARM?
NATCOPHARM has a 52-week high of ₹N/A and low of ₹N/A.
What is NATCOPHARM's operating profit margin trend?
NATCOPHARM has a 5-year average Operating Profit Margin (OPM) of 38.03%, indicating the company's operational efficiency.
How is NATCOPHARM's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -0.59% and YoY Profit Growth of -23.46%.
What is the institutional holding pattern in NATCOPHARM?
NATCOPHARM has FII holding of 14.09% and DII holding of 5.87%. Significant institutional holding often suggests professional confidence in the stock.